Our Strategy

Getting to “Leading pharmaceutical company”

Our goal is to be a leading pharmaceutical company focused on the development, manufacture, and commercialization of branded pharmaceutical products that use our proprietary extended-release drug delivery technology platform. The 505(b)(2) regulatory approval pathway allows for a potentially streamlined and targeted clinical development program. To achieve this goal, key elements of our business strategy include:

  • Successfully launch our first branded orally disintegrating tablet
  • Obtain U.S. Food and Drug Administration, or FDA, approval for our other two product candidates in ADHD
  • Manufacture our proprietary products in our FDA- and DEA-registered manufacturing facilities
  • Leverage our proprietary technology platform to develop additional product candidates in Central Nervous System (CNS) and other therapeutic areas
  • Continue to expand our robust intellectual property portfolio covering our proprietary extended-release drug delivery technology platform and products